Adeno-Associated Virus Vector-Mediated Liver Gene Therapy for Crigler-Najjar Syndrome | CureCN | Project | News & Multimedia | H2020 | CORDIS | European Commission

Projektinformationen

CureCN

ID Finanzhilfevereinbarung: 755225

DOI 10.3030/755225

Projekt abgeschlossen

EK-Unterschriftsdatum 5 Dezember 2017

Startdatum 1 Januar 2018

Enddatum 30 Juni 2023

Finanziert unter

SOCIETAL CHALLENGES - Health, demographic change and well-being
Treating and managing disease

Gesamtkosten € 6 249 103,75

EU-Beitrag € 6 249 103,75

6 249 103,75

Koordiniert durch

ASSOCIATION GENETHON
France

Projekthintergründe

Gene therapy trials point to cure for rare liver disease
EN

Nachrichten

Scientific advances

Clinical trial gives hope to sufferers of rare genetic liver disease

21 Juli 2021

Scientific advances

Finding a curative gene therapy for the so-far incurable Crigler-Najjar syndrome: EU project CureCN releases animated clip

9 Juni 2020

Scientific advances

EU Research Project CureCN Releases Video Clip

3 August 2018

Scientific advances

New Research Project CureCN Aims to Cure the Ultra-Rare Crigler-Najjar Syndrome

5 Juli 2018

Diese Seite teilen

Herunterladen

XML
PDF

Letzte Aktualisierung: 28 Dezember 2022

Mein Booklet

Permalink: https://cordis.europa.eu/project/id/755225/news/de

European Union, 2024